Catalent on Monday said it will sell its oral solids development and small-scale manufacturing facility in Somerset to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden.
Financial details of the agreement, which is expected to close in early 2025, have not been disclosed.
The Somerset property doubles as Catalent’s corporate headquarters, and the CDMO will maintain its home base at the site for now before shifting to a new location sometime in the future.
Catalent said the new location of the corporate headquarters will be announced at a later date.
Beyond Somerset, Catalent says it’s invested in its oral solid firepower at other facilities in the U.S. and Europe, expanding its ability to perform commercial spray drying, high potent API handling and manufacturing writ large.
Ardena’s purchase of the site, which employs roughly 200 scientists and technicians, positions the company to pitch its services to pharmas and biotechs on both sides of the Atlantic.
“We are thrilled to welcome the talented scientific and operations team from Somerset into the Ardena family,” Jeremie Trochu, Ardena’s CEO, said in a statement. “Together, we will continue to support biopharma companies at the cutting edge of innovation to deliver life-changing therapies to patients worldwide.”
